The FDA’s authorization of the Q-Collar is under scrutiny after researchers identified duplicated data, altered study endpoints, and unsubstantiated “brain protection” claims.
Researchers found that written exposure therapy and SSRIs both reduced PTSD symptoms in primary care, while switching to venlafaxine benefited nonresponders.